ENPICOM, an innovative bioinformatics software engineering company, announced that Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative, research-based, commercial-stage biopharmaceutical company based in China and the U.S., has signed a subscription agreement for ENPICOM\u2019s IGX Platform. The IGX Platform with its Antibody Discovery Module (ADM) is a software platform engineered to assist researchers in diversifying and improving their candidate pools by selecting genetic sequences relating to a set of desired therapeutic characteristics from a database of millions of such sequences. Zai Lab intends to implement Next Generation Sequencing (NGS) as an additional technology to optimize its antibody selection.<\/p>\n\n\n\n
\u201cZai Lab is a leader in innovative drug discovery and development in China, conducting many discovery, preclinical, and clinical programs around the world. We are delighted to provide them with the IGX Platform to optimize their antibody discovery workflow and to accelerate the development of innovative drugs,<\/em>\u201d said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM.<\/p>\n\n\n\n Efficient analysis of NGS data provides a more targeted and streamlined selection of antibodies to express and analyze in the lab. This results in more diversified candidate pools and identification of candidates with improved characteristics. The analysis of both Sanger and NGS data together for antibody discovery requires specialized software that provides:<\/p>\n\n\n\nEnabling targeted and efficient candidate selection with integrated bulk NGS, single cell sequencing and Sanger data analysis<\/strong><\/h4>\n\n\n\n